Iovance Biotherapeutics, Inc.IOVA
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · iovance.com
Iovance Biotherapeutics, Inc. develops and delivers tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Its Amtagvi (lifileucel) is the first FDA-approved one-time treatment for previously treated advanced melanoma, approved in three global markets and available at more than 95 authorized treatment centers. The company operates fully owned, centralized U.S.-based manufacturing.
Key ratios
FCF / Sales
-91.2%TTM
2025
-127.6%2024
-221.9%2023
-32305.1%
Net margin
-89.1%TTM
2025
-148.4%2024
-226.8%
ROA
-20.3%TTM
2025
-27.3%2024
-29.2%2023
-39.9%
ROE
-55.5%2025
2024
-57.5%2023
-81.9%
Revenue growth
34.6%TTM
2025
60.6%2024
13699.0%
Recent news
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Track IOVA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer